Optos Announcements

RNS Number : 1028H Optos plc 31 October 2008  
?
OPTOS PLC
(the "Company")

FY'09 FINANCIAL CALENDAR

LONDON, UK, 31 October 2008 - Optos plc (LSE: OPTS), the leading medical retinal imaging technology company, is today confirming the following key announcement dates for the financial year ending 30 September 2009.

EVENT
DATE
(DD/MM/YY)

Interim Management Statement (Q1-09)
29-01-2009
Pre-Close Statement (six months ending 31 March 2009)
31-03-2009
Interim Financial Results
20-05-2009
Interim Management Statement (Q3-09)
30-07-2009
Pre Close Statement (year ending 30 September 2009)
30-09-2009
Preliminary Results Announcement
02-12-2009

The Company will issue its preliminary results statement for the year ended 30 September 2008 on 4 December 2008 and will hold its 2008 Annual General Meeting on 26 February 2009 commencing at 11h00 GMT at the offices of Maclay Murray & Spens LLP, One London Wall, London EC2Y 5AB.

Enquiries

Optos plc
+44 (0)1383 843337
John McNeil, Company Secretary

Maitland
+44 (0)20 7379 5151
Brian Hudspith / Neil Bennett

About Optos plc

Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to detect clinically with conventional examination equipment and techniques. Optos' devices produce ultra wide-field, high resolution images of approximately 82% of the retina, something no other device is capable of doing in any one image. The images provide optometrists and ophthalmologists with enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. Optos has a range of medical devices that support different customer segments and patient levels: P200 device is concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; P200C device is designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; P200MA device supports retinal specialists, working primarily with a diabetic patient base, in the medical care market through an advanced medical angiography procedure. Optos' technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for the practitioner and patient resulting in more targeted treatment regimes and improved patient outcomes. This can help save sight and save lives. Optos estimates that it is addressing a market opportunity with a combined $4 billion potential. 
Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNSThe company news service from the London Stock Exchange  END  MSCILFSDIELIVIT